Higher levels of matrix metalloproteinase-3 in patients with RA reflect disease activity and structural damage

Skácelová, Martina; Heřmanová, Zuzana; Horák, Pavel; Ahmed, Kazi Gias Uddin; Langová, Kateřina

doi:10.5507/bp.2017.015

Cited by 14 publications

(9 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ММП-3 (стромелизин 1)это протеолитический фермент, который синтезируется В-клетками и синовиальными фибробластами, экспрессируется в ткани паннуса, активирует проколлагеназу и способствует разрушению хряща [51][52][53]. Известно, что ММП-3 отражает активность РА и позволяет прогнозировать развитие эрозий [54,55]. Высокий уровень ММП-3 у АЦЦП-негативных пациентов с недифференцированным артритом может быть преди ктором развития РА (ДЧ=63,6%; ДС=81,5%) [56,57].…”

Section: иммунологическая характеристикаunclassified

ACCP-negative rheumatoid arthritis – clinical and immunological features

Dibrov¹

2022

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Depending on the presence of laboratory biomarkers: rheumatoid factor IgM and anti-cyclic citrullinated peptide antibodies (ACCP), “seropositive” and “seronegative” variants of rheumatoid arthritis (RA) are distinguished. Immunological subtypes differ in risk factors, immunopathogenesis, and the course of the disease. A review of data concerning immunology and clinical features of ACCP-negative rheumatoid arthritis is presented. The presence of ACCP in the peripheral blood reflects the progressive erosive process with a predominance of the inflammatory component and involvement of the B cells. Proliferative changes predominate in the ACCPnegative subtype; disorders associated with the T-cell link, primarily with CD4+ T-lymphocytes, play an important role in pathogenesis. This variant of the disease is characterized by a less pronounced erosive process, but the inflammatory activity in both subtypes of RA can be comparable. Early diagnosis, regular monitoring of the disease activity and the «treat to target» strategy are recommended for both positive and negative ACCP RA, however, the effectiveness of individual drugs in these subtypes may vary significantly.

show abstract

Section: иммунологическая характеристикаunclassified

ACCP-negative rheumatoid arthritis – clinical and immunological features

Dibrov¹

2022

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

show abstract

“…As the 'best available indirect evidence' to assess the presence of inflammatory activity in RA patients in whom there was not explicit doubt about the presence of inflammatory activity, MMP-3 and the MBDA score were studied most extensively in studies reporting the appropriate diagnostic association measures with low to moderate RoB. 34 35 56 64 However, for MMP-3, no validated cut-off was found 35 64 and, for the MBDA score, the cut-off could not be validated in all studies, 101-104 106 limiting the applicability for use in daily practice. At joint level, studies with low to moderate RoB assessing US as well as other diagnostic tests with the preferred reference standard at joint level (ie, clinically swollen joints) were not found.…”

Section: Rheumatoid Arthritis Rheumatoid Arthritis Rheumatoid Arthritismentioning

confidence: 99%

Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis

et al. 2021

View full text Add to dashboard Cite

ObjectivesTo summarise the evidence on diagnostic issues in difficult-to-treat rheumatoid arthritis (D2T RA) informing the EULAR recommendations for the management of D2T RA.MethodsA systematic literature review (SLR) was performed regarding the optimal confirmation of a diagnosis of rheumatoid arthritis (RA) and of mimicking diseases and the assessment of inflammatory disease activity. PubMed and Embase databases were searched up to December 2019. Relevant papers were selected and appraised.ResultsEighty-two papers were selected for detailed assessment. The identified evidence had several limitations: (1) no studies were found including D2T RA patients specifically, and only the minority of studies included RA patients in whom there was explicit doubt about the diagnosis of RA or presence of inflammatory activity; (2) mostly only correlations were reported, not directly useful to evaluate the accuracy of detecting inflammatory activity in clinical practice; (3) heterogeneous, and often suboptimal, reference standards were used and (4) (thus) only very few studies had a low risk of bias.To ascertain a diagnosis of RA or relevant mimicking disease, no diagnostic test with sufficient validity and accuracy was identified. To ascertain inflammatory activity in patients with RA in general and in those with obesity and fibromyalgia, ultrasonography (US) was studied most extensively and was found to be the most promising diagnostic test.ConclusionsThis SLR highlights the scarcity of high-quality studies regarding diagnostic issues in D2T RA. No diagnostic tests with sufficient validity and accuracy were found to confirm nor exclude the diagnosis of RA nor its mimicking diseases in D2T RA patients. Despite the lack of high-quality direct evidence, US may have an additional value to assess the presence of inflammatory activity in D2T RA patients, including those with concomitant obesity or fibromyalgia.

show abstract

“…The FLS overactivity is a pathological condition that usually co-exists with the upregulation of MMPs [3,7]. Remarkable increases in the circulating levels of MMP-1 (collagenase) and MMP-3 (stromelysin 1) have been documented in population-based studies of RA [8][9][10][11]. Moreover, MMP-3 has been widely suggested as a surrogate biomarker to monitor and emerge the extent of damages in afflicted joints [11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, MMP-3 has been widely suggested as a surrogate biomarker to monitor and emerge the extent of damages in afflicted joints [11][12][13][14]. Epidemiologic studies have provided sufficient evidence to show MMPs associated with increased disease activity scores in 28 joints (DAS28) [8,[11][12][13], which is a clinical reference for RA [15].…”

Section: Introductionmentioning

confidence: 99%

Stachys schtschegleevii tea, matrix metalloproteinase, and disease severity in female rheumatoid arthritis patients: a randomized controlled clinical trial

et al. 2021

View full text Add to dashboard Cite

Background Stachys schtschegleevii (SSC) is a herbal medicine used to treat infections. To date, this is the first study aimed to investigate the effects of SSC tea on disease activity score (DAS), serum inflammatory biomarkers and matrix metalloproteinases (MMP-1 and MMP-3) among women with rheumatoid arthritis (RA). Methods This pilot, triple-blind, randomized controlled clinical trial was conducted among forty-four women (age: 30-65 years) diagnosed with moderately active RA. Subjects were randomly assigned (1:1 ratio) into either SSC group (2.4 g/day SSC + 2.4 g/day black tea, n=22) or placebo (2.4 g/day black tea, n=22) for 8 weeks. Serum high-sensitivity C-reactive protein (hs-CRP), interleukin-1 beta (IL-1β), and MMPs were measured using ELISA. According to the American College of Rheumatology guideline considering hs-CRP, DAS28 was assessed. Results Both study groups had respondent rates above 94.9%. The SSC intervention caused significant reductions in the number and the percent changes of the tender joints (SSC: −74.39% vs. placebo: −57.15%, mean differences= −0.77; P<0.05) and DAS28 [SSC: −32.44% vs. placebo: −22.32%, mean differences= −0.41, P<0.05). Unlike the intervention within SSC group that showed significant reductions in the mean serum levels of hs-CRP, IL-1β, and MMP-3, SSC caused significant MMP-3 reductions (SSC: −20.59% vs. placebo: 1.29%, P<0.05). ConclusionThe SSC intervention showed an appropriate clinical efficacy for female RA patients, accompanying remarkable reductions in the number of tender and swollen joints, DAS28, and serum levels of MMP-3. This can provide additional insights to the interventional studies controlling RA-related pathological and inflammatory outcomes. Trial registrationProspectively registered at the Iranian Registry of Clinical Trials (IRCT), linked to the WHO Registry Network (https:// en. irct. ir/ trial/ 11602, IRCT registration number: IRCT2015032011335N5, Registration date:2015-05-12). Key Points• Stachys schtschegleevii improved clinical outcomes and attenuated disease severity in RA patients.• Stachys schtschegleevii ameliorated serum level of

show abstract

Higher levels of matrix metalloproteinase-3 in patients with RA reflect disease activity and structural damage

Cited by 14 publications

References 34 publications

ACCP-negative rheumatoid arthritis – clinical and immunological features

ACCP-negative rheumatoid arthritis – clinical and immunological features

Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis

Stachys schtschegleevii tea, matrix metalloproteinase, and disease severity in female rheumatoid arthritis patients: a randomized controlled clinical trial

Contact Info

Product

Resources

About